Ontology highlight
ABSTRACT: Background
Angiotensin-converting enzyme 2 is the receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses for entry into lung cells. Because ACE-2 may be modulated by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEIs and ARBs are at higher risk of coronavirus disease 2019 (COVID-19) pneumonia.Aim
This study sought to analyze the association of COVID-19 pneumonia with previous treatment with ACEIs and ARBs.Materials and methods
We retrospectively reviewed 684 consecutive patients hospitalized for suspected COVID-19 pneumonia and tested by polymerase chain reaction assay. Patients were split into two groups, according to whether (group 1, n = 484) or n
SUBMITTER: Georges JL
PROVIDER: S-EPMC7751849 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature